Best New Stocks — Dicerna Pharmaceuticals (DRNA)
IPO Return: 146.5%
Dicerna Pharmaceuticals (DRNA) is a biotech company that focuses on treatments for rare inherited diseases, such as for those affecting the liver or for cancers. To do this, company has developed a proprietary RNA interference (RNAi) platform. This year, it plans to begin clinical trials of its lead candidate.
In terms of the go-to-market strategy, Dicerna has a two-pronged approach. For rare-disease drugs, the company will put together a small sales force. Keep in mind that these types of treatments get government subsidies.
As for the oncology drugs, Dicerna will rely on a partnership strategy. And yes, the company already has a major partner, Kyowa Hakko Kirin.